SUPERVALU (NYSE: SVU ) is expected to report Q2 earnings around Oct. 11. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict SUPERVALU's revenues will drop -4.3% and EPS will contract -46.4%.
The average estimate for revenue is $8.07 billion. On the bottom line, the average EPS estimate is $0.15.
Last quarter, SUPERVALU booked revenue of $10.59 billion. GAAP reported sales were 4.7% lower than the prior-year quarter's $11.11 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.19. GAAP EPS of $0.19 for Q1 were 46% lower than the prior-year quarter's $0.35 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 22.0%, 10 basis points worse than the prior-year quarter. Operating margin was 2.0%, 50 basis points worse than the prior-year quarter. Net margin was 0.4%, 30 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $34.53 billion. The average EPS estimate is $0.70.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 854 members out of 940 rating the stock outperform, and 86 members rating it underperform. Among 230 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 207 give SUPERVALU a green thumbs-up, and 23 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on SUPERVALU is hold, with an average price target of $6.94.
If you're interested in retailers like SUPERVALU as investments, you should check out the retail concept that is The Motley Fool's top stock for 2012. Its founder wrote the book on big box retailing, and it's growing in increasingly important international markets. Click here for instant access to this free report.
- Add SUPERVALU to My Watchlist.